These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 15824253)

  • 1. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
    Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
    Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
    Parry A; Corkill R; Blamire AM; Palace J; Narayanan S; Arnold D; Styles P; Matthews PM
    J Neurol; 2003 Feb; 250(2):171-8. PubMed ID: 12574947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
    Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
    Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM; Peppler R; VanderBrug Medendorp S; Lehmann P; Alam J
    Ann Neurol; 1996 Oct; 40(4):618-27. PubMed ID: 8871582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier.
    Niemelä J; Ifergan I; Yegutkin GG; Jalkanen S; Prat A; Airas L
    Eur J Immunol; 2008 Oct; 38(10):2718-26. PubMed ID: 18825744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
    Stone LA; Frank JA; Albert PS; Bash C; Smith ME; Maloni H; McFarland HF
    Ann Neurol; 1995 May; 37(5):611-9. PubMed ID: 7755356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of brain atrophy in benign vs early multiple sclerosis.
    Gauthier SA; Berger AM; Liptak Z; Duan Y; Egorova S; Buckle GJ; Glanz BI; Khoury SJ; Bakshi R; Weiner HL; Guttmann CR
    Arch Neurol; 2009 Feb; 66(2):234-7. PubMed ID: 19204160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro.
    Kraus J; Ling AK; Hamm S; Voigt K; Oschmann P; Engelhardt B
    Ann Neurol; 2004 Aug; 56(2):192-205. PubMed ID: 15293271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis.
    Wang D; Ayers MM; Catmull DV; Hazelwood LJ; Bernard CC; Orian JM
    Glia; 2005 Aug; 51(3):235-40. PubMed ID: 15812814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interferon-beta on oligodendroglial cells.
    Heine S; Ebnet J; Maysami S; Stangel M
    J Neuroimmunol; 2006 Aug; 177(1-2):173-80. PubMed ID: 16753226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
    Caggiula M; Batocchi AP; Frisullo G; Angelucci F; Patanella AK; Sancricca C; Nociti V; Tonali PA; Mirabella M
    Clin Immunol; 2006 Jan; 118(1):77-82. PubMed ID: 16275091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
    Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
    Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon inhibitory activity in patients with multiple sclerosis.
    Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
    Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis.
    Weinstock-Guttman B; Zivadinov R; Tamaño-Blanco M; Abdelrahman N; Badgett D; Durfee J; Hussein S; Feichter J; Patrick K; Benedict R; Ramanathan M
    J Neuroimmunol; 2007 Aug; 188(1-2):167-74. PubMed ID: 17602759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
    Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
    Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis.
    Ifergan I; Wosik K; Cayrol R; Kébir H; Auger C; Bernard M; Bouthillier A; Moumdjian R; Duquette P; Prat A
    Ann Neurol; 2006 Jul; 60(1):45-55. PubMed ID: 16729291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.